Hypofractionated radiotherapy for localized prostate cancer: the protocol for a prospective clinical trial.

Yiyin Liang, Weiwei Zhang, Xianzhi Zhao, Huojun Zhang

Registry-linked trialAbstract readClinical Trial Protocol

In one paragraph

Article in Future oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06325774 (Safety and Efficacy Study of Hypofractionated Radiotherapy for Localized Prostate Cancer), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06325774 narecruitingnot on this map

Safety and Efficacy Study of Hypofractionated Radiotherapy for Localized Prostate Cancer: a Single-arm Clinical Trial

TypeinterventionalSponsorChanghai HospitalRan2024 to 2031Enrolled20ConditionsLocalized Prostate CancerArmsHypofractionated radiation therapy

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yiyin LiangDepartment of Radiation Oncology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China.ORCID 0009-0007-4328-6116

Weiwei ZhangDepartment of Radiation Oncology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China.

Xianzhi ZhaoDepartment of Radiation Oncology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China.

Huojun ZhangDepartment of Radiation Oncology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeCompared to conventional fractionated radiotherapy (CFRT), which delivers lower doses over a longer period, moderate hypofractionated radiotherapy (HFRT) administers higher doses in a shorter period. Increasing evidence has demonstrated that the safety and efficacy of moderate HFRT in 20-28 fractions for localized PCa are equal to those of CFRT. However, the optimal and lowest fractions of moderate HFRT need to be explored for localized PCa. Therefore, this trial aims to investigate the safety outcomes of HFRT in 15 fractions for treating patients with localized PCa. METHODS AND ANALYSIS: This is a single-center, single-arm, open-label clinical trial. Patients with localized PCa will be enrolled to receive HFRT (54 Gy delivered in 15 daily fractions of 3.6 Gy). The primary outcome measures are the incidence of radiotherapy-related gastrointestinal (GI) and genitourinary (GU) symptoms and erectile dysfunction. Secondary outcome measures include biochemical progression-free survival (bPFS), local progression-free survival (LPFS), distant metastasis-free survival (DMFS), overall survival (OS), and quality of life (QoL). CLINICAL

trial registrationNCT06325774 (Clinicaltrials.gov).

Indexed as

Prostatic NeoplasmsRadiation Dose HypofractionationDose Fractionation, RadiationHumansMaleProgression-Free SurvivalProspective StudiesQuality of LifeTreatment Outcomebiochemical recurrence-free survivalgastrointestinal and genitourinary toxicitieshypofractionated radiotherapyprospectiveProstate cancer

Identifiers

PMID40257456

DOI10.1080/14796694.2025.2489340

PMCPMC12077468

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

NCT06325774ClinicalTrials.gov

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.